<DOC>
	<DOCNO>NCT01553721</DOCNO>
	<brief_summary>This placebo-controlled , double-blind , phase II clinical study evaluate efficacy safety Udenafil patient Pulmonary Arterial Hypertension ( PAH ) .</brief_summary>
	<brief_title>Efficacy Safety Study Udenafil Patient With Pulmonary Arterial Hypertension ( PAH )</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<mesh_term>Udenafil</mesh_term>
	<criteria>• Subjects age 18 follow disease primary Pulmonary Arterial Hypertension secondary Pulmonary Arterial Hypertension cause connective tissue disease [ Phase IIb ] Pulmonary Arterial Hypertension cause congenital heart disease ( include Eisenmenger syndrome ) Subjects pulmonary arterial hypertension cause etiology specify inclusion criterion BMI ( Body Mass Index ) &lt; 18.5kg/m2 Subjects hypotension ( SBP/DBP &lt; 90/50mmHg ) uncontrolled hypertension ( SBP/DBP &gt; 170/100mmHg ) Creatinine clearance ≤ 30mL/min History nonarteritic anterior ischemic optic neuropathy ( NAION )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>